Cingulate Inc. (CING) vs RenovoRx, Inc. (RNXT)

Cingulate Inc. and RenovoRx, Inc. are both Biotechnology companies. Cingulate Inc. and RenovoRx, Inc. are of similar size ($75.8M and $73.6M). Cingulate Inc. has the higher net margin (0.00% vs −621.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Cingulate Inc. leads on 6 and RenovoRx, Inc. on 6.

Valuation

Metric CING RNXT Biotechnology median
P/E n/m n/m 7.88
P/S n/m 39.73 11.47
P/B 2.73 8.74 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 37.37 10.73
Earnings yield (74.02%) (18.67%) (28.84%)
Free cash flow yield (32.74%) (15.20%) (23.03%)

Profitability

Metric CING RNXT Biotechnology median
Gross margin 0.00% 84.41% 65.16%
Operating margin 0.00% (685.22%) 0.00%
Net margin 0.00% (621.71%) 0.00%
Free cash flow margin 0.00% (604.10%) 0.00%
Return on equity (198.74%) (125.23%) (57.72%)
Return on assets (123.76%) (97.83%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CING RNXT Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 56.47% 20.00% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CING RNXT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.50 5.74 4.73
Net debt to EBITDA 0.51 0.56 0.96

Dividend

Metric CING RNXT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CING RNXT Biotechnology median
Market cap 73.58m 75.82m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack